Trial Profile
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Ibrutinib; Obinutuzumab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 17 Jun 2021 Planned End Date changed from 31 Oct 2025 to 7 May 2028.
- 17 Jun 2021 Planned primary completion date changed from 7 May 2021 to 7 May 2028.
- 01 May 2021 Planned primary completion date changed from 31 Oct 2025 to 7 May 2021.